Approaches to first-line treatment for EGFR mutant and ALK translocated patients

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Rationale for treatment decisions of patients with metastatic NSCLC
Topics Anti-Cancer Agents & Biologic Therapy
Biomarkers
Non-Small-Cell Lung Cancer, Metastatic
Lung and other Thoracic Tumours
Personalised Medicine
Presenter Tetsuya Mitsudomi
Authors T. Mitsudomi
  • -, Kindai University School of Medicine, 577-8502 - Osaka/JP